Atara Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary

Atara Biotherapeutics

09/05/2024 21:48

* Atara Biotherapeutics Inc  ATRA.OQ  reported a quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -72 cents.  The mean expectation of
four analysts for the quarter was for a loss of 26 cents per
share. Wall Street expected results to range from -33 cents
to -17 cents per share.
    * Revenue rose 2,131.4% to $27.36 million from a year ago;
analysts expected $24.69 million. 
    * Atara Biotherapeutics Inc shares had fallen by 18.5% this
quarter and gained 10.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 45.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $1.65 
This summary was machine generated from LSEG data May 9 at 08:47
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.26          -0.23          Beat
 Dec. 31 2023      -0.48          -0.56          Missed
 Sep. 30 2023      -0.66          -0.66          Met
 Jun. 30 2023      -0.67          -0.68          Missed